Applied DNA Sciences (APDN) announced the completion of the buildout of its new Good Manufacturing Practices manufacturing facility within its Stony Brook, New York, headquarters and readiness to accept orders for the manufacture of LineaDNA IVT templates that clients can utilize for the production of mRNA clinical trial materials. The facility is undergoing final testing and is expected to be fully operational by the end of the current month. The Company also announced that it is actively negotiating a supply agreement for GMP IVT template with a mRNA therapeutic developer. Separately, the Company reaffirmed its intention to complete the implementation of its previously announced strategic restructuring plan by the end of the current quarter. The restructuring is intended to drive sustainable growth from LineaRx, Inc., its biotherapeutic subsidiary, optimize Applied DNA’s cost structure, and extend the parent company’s cash runway.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.